Environmental Allergens Trigger Type 2 Inflammation Through Ripoptosome Activation
By LabMedica International staff writers Posted on 27 Sep 2021 |
Image: BD LSRFortessa is a high-end cell analyzer. It is equipped with four lasers allowing for up to 16 colors (18 parameters) analysis (Photo courtesy of ETH Zurich)
Environmental allergens, including fungi, insects and mites, trigger type 2 immunity; however, the innate sensing mechanisms and initial signaling events remain unclear. The allergens trigger activity among an interlocked set of cell death-inducing signals called the ripoptosome.
Although myeloid cells prime adaptive immunity in generating IgE3 and type 2 T helper cell (Th2) responses, allergens are initially recognized by the innate immune system, triggering downstream responses leading to production of type 2 effectors, before the initiation of adaptive immunity.
Immunologists and their colleagues at the Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) recently reported that allergens trigger RIPK1–caspase 8 ripoptosome activation in epithelial cells. The active caspase 8 subsequently engages caspases 3 and 7, which directly mediate intracellular maturation and release of interleukin-33 (IL-33), a pro-atopy, innate immunity, alarmin cytokine. The team used different cell line and murine models. Data were acquired on a BD LSRFortessa flow cytometer (BD Biosciences, San Jose, CA, USA). In IL-33 secretion assays, the concentration of released IL-33 in cell culture supernatants was determined by ELISA (R&D Systems, Minneapolis, MN, USA).
The team reported that mature IL-33 maintained functional interaction with the cognate ST2 receptor and elicited potent pro-atopy inflammatory activity in vitro and in vivo. Inhibiting caspase 8 pharmacologically and deleting murine Il33 and Casp8 each attenuated allergic inflammation in vivo. Clinical data substantiated ripoptosome activation and IL-33 maturation as likely contributors to human allergic inflammation. They found that in the human allergic disease eosinophilic esophagitis ripoptosome activation markers and mature IL-33 levels dynamically correlated with the degree of esophageal eosinophilia and disease activity.
Marc Rothenberg, MD, PhD, Director of the Division of Allergy and Immunology at Cincinnati Children’s and senior author on the study, said, “Disrupting this allergen sensing pathway could provide a unique opportunity to counteract type 2 immunity and alleviate allergic inflammation.”
The authors concluded that their findings reveal an epithelial barrier, allergen-sensing mechanism that converges on the ripoptosome as an intracellular molecular signaling platform, triggering type 2 innate immune responses. These findings have significant implications for understanding and treating human allergic diseases. The study was published on September 16, 2021 in the journal Nature Immunology.
Related Links:
Cincinnati Children’s Hospital Medical Center
BD Biosciences
R&D Systems
Although myeloid cells prime adaptive immunity in generating IgE3 and type 2 T helper cell (Th2) responses, allergens are initially recognized by the innate immune system, triggering downstream responses leading to production of type 2 effectors, before the initiation of adaptive immunity.
Immunologists and their colleagues at the Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) recently reported that allergens trigger RIPK1–caspase 8 ripoptosome activation in epithelial cells. The active caspase 8 subsequently engages caspases 3 and 7, which directly mediate intracellular maturation and release of interleukin-33 (IL-33), a pro-atopy, innate immunity, alarmin cytokine. The team used different cell line and murine models. Data were acquired on a BD LSRFortessa flow cytometer (BD Biosciences, San Jose, CA, USA). In IL-33 secretion assays, the concentration of released IL-33 in cell culture supernatants was determined by ELISA (R&D Systems, Minneapolis, MN, USA).
The team reported that mature IL-33 maintained functional interaction with the cognate ST2 receptor and elicited potent pro-atopy inflammatory activity in vitro and in vivo. Inhibiting caspase 8 pharmacologically and deleting murine Il33 and Casp8 each attenuated allergic inflammation in vivo. Clinical data substantiated ripoptosome activation and IL-33 maturation as likely contributors to human allergic inflammation. They found that in the human allergic disease eosinophilic esophagitis ripoptosome activation markers and mature IL-33 levels dynamically correlated with the degree of esophageal eosinophilia and disease activity.
Marc Rothenberg, MD, PhD, Director of the Division of Allergy and Immunology at Cincinnati Children’s and senior author on the study, said, “Disrupting this allergen sensing pathway could provide a unique opportunity to counteract type 2 immunity and alleviate allergic inflammation.”
The authors concluded that their findings reveal an epithelial barrier, allergen-sensing mechanism that converges on the ripoptosome as an intracellular molecular signaling platform, triggering type 2 innate immune responses. These findings have significant implications for understanding and treating human allergic diseases. The study was published on September 16, 2021 in the journal Nature Immunology.
Related Links:
Cincinnati Children’s Hospital Medical Center
BD Biosciences
R&D Systems
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms